CRP and metabolic syndrome: Long-term use of HAART has been associated with multiple metabolic and immunologic abnormalities such as dyslipidemia (total cholesterol >220 mg/dL), insulin resistance (glycosylated hemoglobin A1C >7%), endothelial dysfunction, and persistent, low-level inflammation (i.e., elevated C-reactive protein) [34–36].